Recursion Pharmaceuticals Stock Investor Sentiment
| RXRX Stock | USD 5.70 0.05 0.87% |
Slightly above 64% of Recursion Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Recursion Pharmaceuticals suggests that many traders are alarmed. Recursion Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Recursion Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Panic Vs Confidence
36
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Recursion Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Recursion Pharmaceuticals.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentDisposing |
Recursion Historical Sentiment
Although Recursion Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Recursion, such as negative comments on social media and news outlets, may cause fear in the market and push Recursion Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Recursion.
Recursion |
Recursion Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Recursion Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Recursion Pharmaceuticals Historical Investor Sentiment
Investor biases related to Recursion Pharmaceuticals' public news can be used to forecast risks associated with an investment in Recursion. The trend in average sentiment can be used to explain how an investor holding Recursion can time the market purely based on public headlines and social activities around Recursion Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Recursion Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Recursion Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Recursion Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Recursion Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Recursion Pharmaceuticals that are available to investors today. That information is available publicly through Recursion media outlets and privately through word of mouth or via Recursion internal channels. However, regardless of the origin, that massive amount of Recursion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Recursion Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Recursion Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Recursion Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Recursion Pharmaceuticals alpha.
Recursion Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 6.04 subject to Rule 16b-3 | 09/04/2024 |
2 | Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 6.14 subject to Rule 16b-3 | 09/05/2024 |
3 | Disposition of 375 shares by Michael Secora of Recursion Pharmaceuticals at 2.22 subject to Rule 16b-3 | 09/10/2024 |
4 | Disposition of 11447 shares by Blake Borgeson of Recursion Pharmaceuticals at 6.8431 subject to Rule 16b-3 | 09/17/2024 |
5 | Disposition of tradable shares by Marriott Tina of Recursion Pharmaceuticals at 1.06 subject to Rule 16b-3 | 09/26/2024 |
6 | Recursion Pharmaceuticals director sells over 71,000 in company stock | 10/03/2024 |
7 | Recursion Pharmaceuticals Shares Up 1.9 percent Heres What Happened | 10/18/2024 |
8 | Disposition of 50000 shares by Christopher Gibson of Recursion Pharmaceuticals subject to Rule 16b-3 | 10/21/2024 |
9 | Disposition of 11447 shares by Blake Borgeson of Recursion Pharmaceuticals at 6.7202 subject to Rule 16b-3 | 10/29/2024 |
10 | Insider Sale Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc | 11/01/2024 |
11 | Recursion Pharmaceuticals Inc Q3 2024 Earnings Report Preview What To Expect | 11/05/2024 |
12 | Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results | 11/06/2024 |
13 | Recursion Pharmaceuticals, Inc.s Share Price Could Signal Some Risk | 11/08/2024 |
14 | FMR LLCs Strategic Acquisition in Recursion Pharmaceuticals Inc | 11/13/2024 |
15 | Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 7.35 subject to Rule 16b-3 | 11/14/2024 |
16 | Recursion Pharmaceuticals CFO Michael Secora sells 229,504 in stock | 11/15/2024 |
17 | 2 Innovative Stocks That Could Deliver Outsize Returns | 11/22/2024 |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.